Recent Finacing
Recent Raise
Eikonizo Therapeutics is a Cambridge, MA biopharmaceutical company developing oral, CNS-penetrant, highly selective HDAC6 small-molecule inhibitors (lead EKZ-102) for ALS and cardiorenal indications, IND-enabling with first-in-human planned 2025.
